Mechanical Ventilation 2.0 System - New paradigm mechanical ventilation for treating and preventing lungs’ diseases (i.e. covid)

This is patented by USPTO (with optional continuation) and pending international patents.

Publication No.: US 2022-0072250

Publication Date: March 10, 2022

Postulated benefits of the technology:

- better clinical outcomes, including: mortality, prevention of ventilator associated pneumonia, need to implement permissive hypercapnia in ARDS, ability to independently set goal pO2 and pCo2
- independence on type of pathogen (new viral strains, toxic warfare agents- it should work independently on the pathogen strain or type, likely no need to study for each another strain, unlike vaccines )
- down-stream benefits, less antibiotics use, less clostridium difficile infections
- better financial outcomes
- shorter “on-ventilator” time,
- shorter ICU stay,
- shorter hospital stay,
- faster recovery,
- shorter “back-to-work” time,
- less healthcare resources utilization
- possibly higher reimbursement in institutions with better clinical outcomes (i.e. due to - less clostridium difficile infection)

- safer for staff
- separation of inspiratory and exploratory lumens prevents release of pathogens into the patient room / hallway / ICU atmosphere, as patients can be suctioned using only inspiratory lumens, the expiatory lumens can be used as suctioning tubes anyways in a close-circuit fashion

- no staff steep learning curve needed
similar procedures to place patient on ventilator, and off ventilator
similar concept about ventilator management

-comparable price to current mechanical ventilators
with adapters, which concepts are within our Intellectual Property Portfolio, technology can be easily extended to currently used ventilators

Watch this 3D animation demo:

Watch this 3D animation of comparison between currently used mechanical ventilation and my invention:

USPTO patent (US 2022-0072250) as allowed for download and review:

USPTO and PTC patent applications for download and review:

Invention presented here can hypothetically:

- improve outcomes by increasing oxygenation especially with low tidal volume ventilation, i.e. ARDS with high PEEP

- improve ARDS outcomes, by increasing Co2 clearance and possibly avoiding the need for permissive hypercapnia while using ARDS-net protocol

- improve chances of recovery by elimination of toxins, bacteria, or viruses (i.e. covid) from the lungs by assuring continuous flow within the airways towards the expiratory lumens

- potentially functionally isolate portions (i.e. left vs. right) of the lungs, to limit the cross contamination of toxins, bacteria, or viruses (i.e. covid)

Contact me regarding licensing and investment queries.

At this point of time statements here provided should be only considered as personal opinions, hypotheses and speculative hopes at most.

Team comprises of two members, founder and inventor Lukasz Kiljanek MD, and CTO Elżbieta Haftek PhD

Łukasz Kiljanek M.D. is a board certified in Internal Medicine, Nephrology and Hypertension. Experienced in Intensive care, Pulmonary, Chest surgery and Cardiology. Clinical researcher, AI and data mining, and programmer

Elżbieta Haftek PhD is engineer, R&D, reliability, system engineering, data science. Ph.D. Material Science and Engineering, M.Sc. Medical Device Innovation (UoM), MILI Fellow at the Carlson School of Management

We are the concept / basic prototype level.

The purpose of this description is to illustrate the concepts, unproven yet benefits of and the fundamentals of the invention “Mechanical Ventilation v2.0” in order to find buyers, who might be interested in purchasing the IP.


Each year, before covid, there were about ~ 2 million ventilated Intensive Care Units (ICU) patients in USA

Ventilated patients usually have high mortality (50%) and for some diseases even higher (COVID 26-97%, H1N1 influenza and others 25-46%)

Mechanical ventilation and complications renders ~ 2.5 x costs $ of ICU stay as of 2005

Patients on ventilators consume very high resources with high morbidity, with longer ICU and hospital stays

Mechanical ventilation now 50 + years, with no major developments in its foundations

Our invention and product may offer solution. It is new paradigm of mechanical ventilation, we call it Mechanical Ventilation 2.0. It was inspired with reports of patients doing poorly once placed on ventilator.

Main features of Mechanical Ventilation 2.0:

Separate inspiratory and expiratory lumen(s) prevents re-breathing of contaminated air and allow for functional separation of lungs portions, which can prevent cross-contamination of i.e. infected air from sick left lung to healthy or healthy yet right lung

Continuous variable flows via inspiratory and expiratory lumens provide clearance of dead space and suspended within diseases causative agents (i.e. covid virions, toxins), allowing for full recovery, and eliminates reinfection of recovered alveoli / pneumocytes

More inflow via inspiratory lumens than outflow via expiratory lumens results in inspiration

More outflow via expiratory lumens than inflow via inspiratory lumens results in expiration

Operator can independently adjust the amount of delivered O2 and cleared amount of CO2
benefit in ARDS, no need to implement permissive hypercapnia with effective respiratory acidosis benefit in severe COPD exacerbation with massive CO2 retention

Adapter allowing to use some benefits of our technology with existing “vents” included in our Intellectual Property portfolio

What we have accomplished until now:

We have a simplified model / prototype.
We proved some concepts and some feasibility subjectively.

Invention and entire IP is for sale for 250 000 000$, this is negotiable and I am opened to all offers.

No offers, deals, sales, acquisitions are valid, until they are expressed in writing and signed by both parties in the presence of notary public.

Please see the following videos for more details and explanations :

Comparison of Contemporary used Mechanical Ventilation and my invention for sale, Mechanical Ventilation 2.0:

USPTO patent (US 2022-0072250) as allowed for download and review:

USPTO and PTC patent applications for download and review:

US 20,220,072,250 issued 2022-03-10   [MORE INFO]

Type of Offer: Sale or Licensing

Asking Price: US$250,000,000

Next Patent »
« More Medical Devices Patents
« More Toxicology Patents

Share on      

CrowdSell Your Patent